TY - JOUR
T1 - Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations
AU - Reck, Martin
AU - Shankar, Geetha
AU - Lee, Anthony
AU - Coleman, Shelley
AU - McCleland, Mark
AU - Papadimitrakopoulou, Vassiliki A.
AU - Socinski, Mark A.
AU - Sandler, Alan
N1 - Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Introduction: Cancer immunotherapy has revolutionized the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). However, specific patient groups (e.g. patients with activating epidermal growth factor receptor [EGFR] mutations) do not appear to derive benefit from immune checkpoint inhibitor (ICI) monotherapy. Combining ICIs, such as atezolizumab, with chemotherapy and/or targeted therapies may help to address this unmet need. Areas covered: Atezolizumab is an anti–programmed death-ligand 1 therapy for several tumor types. We review its clinical efficacy and safety in the treatment of advanced or metastatic NSCLC, with a specific focus on the combination of atezolizumab with bevacizumab, carboplatin, and paclitaxel (ABCP). Data from IMpower150 show that the ABCP regimen provided clinical benefit to patients with non-squamous NSCLC, including those with EGFR mutations. Expert opinion: Combining ICIs with chemotherapy has proven to be superior to chemotherapy alone. However, tumor resistance to ICIs will likely increase as these drugs enter earlier lines of therapy, underscoring a need for effective treatments when immunotherapy fails. Data suggest that the ABCP regimen may circumvent ICI resistance mechanisms. Continued investigation into the regimen’s mechanisms, improved patient profiling/selection, and treatment personalization will drive further development/discoveries.
AB - Introduction: Cancer immunotherapy has revolutionized the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). However, specific patient groups (e.g. patients with activating epidermal growth factor receptor [EGFR] mutations) do not appear to derive benefit from immune checkpoint inhibitor (ICI) monotherapy. Combining ICIs, such as atezolizumab, with chemotherapy and/or targeted therapies may help to address this unmet need. Areas covered: Atezolizumab is an anti–programmed death-ligand 1 therapy for several tumor types. We review its clinical efficacy and safety in the treatment of advanced or metastatic NSCLC, with a specific focus on the combination of atezolizumab with bevacizumab, carboplatin, and paclitaxel (ABCP). Data from IMpower150 show that the ABCP regimen provided clinical benefit to patients with non-squamous NSCLC, including those with EGFR mutations. Expert opinion: Combining ICIs with chemotherapy has proven to be superior to chemotherapy alone. However, tumor resistance to ICIs will likely increase as these drugs enter earlier lines of therapy, underscoring a need for effective treatments when immunotherapy fails. Data suggest that the ABCP regimen may circumvent ICI resistance mechanisms. Continued investigation into the regimen’s mechanisms, improved patient profiling/selection, and treatment personalization will drive further development/discoveries.
KW - Atezolizumab
KW - bevacizumab
UR - http://www.scopus.com/inward/record.url?scp=85076393428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076393428&partnerID=8YFLogxK
U2 - 10.1080/17476348.2020.1701439
DO - 10.1080/17476348.2020.1701439
M3 - Article
C2 - 31829747
AN - SCOPUS:85076393428
SN - 1747-6348
VL - 14
SP - 125
EP - 136
JO - Expert Review of Respiratory Medicine
JF - Expert Review of Respiratory Medicine
IS - 2
ER -